Patents by Inventor Kevin J. Wilson

Kevin J. Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND USES THEREOF
    Publication number: 20250066354
    Abstract: The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
    Type: Application
    Filed: October 25, 2024
    Publication date: February 27, 2025
    Inventors: Shawn E.R. SCHILLER, Solymar NEGRETTI, David S. HUANG, Kevin J. WILSON, Melek Nihan UCISIK, Richard CALDWELL
  • EGFR inhibitors
    Patent number: 12172983
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: December 24, 2024
    Assignee: Blueprint Medicines Corporation
    Inventors: John Emmerson Campbell, Thomas A. Dineen, Natasja Brooijmans, Jason D. Brubaker, Meredith Suzanne Eno, Joseph L. Kim, Aysegül Özen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Christopher De Savi
  • INHIBITORS OF RET
    Publication number: 20240417386
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: January 25, 2024
    Publication date: December 19, 2024
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20240382483
    Abstract: The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 21, 2022
    Publication date: November 21, 2024
    Inventors: Natasja Brooijmans, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • COMPOUNDS AND USES THEREOF
    Publication number: 20240376121
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: May 10, 2022
    Publication date: November 14, 2024
    Inventors: Matthew NETHERTON, Francois BRUCELLE, Jing DENG, Johannes H. VOIGT, Kevin J. WILSON
  • Compounds and uses thereof
    Patent number: 12139487
    Abstract: The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
    Type: Grant
    Filed: May 11, 2023
    Date of Patent: November 12, 2024
    Assignee: Foghorn Therapeutics Inc.
    Inventors: Shawn E. R. Schiller, Solymar Negretti, David S. Huang, Kevin J. Wilson, Melek Nihan Ucisik, Richard Caldwell
  • COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT
    Publication number: 20240317757
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Application
    Filed: October 23, 2023
    Publication date: September 26, 2024
    Applicant: Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20240308981
    Abstract: The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 21, 2022
    Publication date: September 19, 2024
    Inventors: Natasja Brooijmans, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20240299387
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 21, 2022
    Publication date: September 12, 2024
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • EGFR INHIBITORS
    Publication number: 20240300946
    Abstract: The present disclosure provides a compound represented by structural formula (I): (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 21, 2022
    Publication date: September 12, 2024
    Inventors: Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE
    Publication number: 20240158398
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: April 20, 2023
    Publication date: May 16, 2024
    Inventors: Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian Lewis Hodous, Joseph L. Kim, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin
  • INHIBITORS OF PROTEIN KINASE A
    Publication number: 20240132490
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least one of the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, processes for making the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and methods of using the same.
    Type: Application
    Filed: February 1, 2022
    Publication date: April 25, 2024
    Applicant: Blueprint Medicines Corporation
    Inventors: Neil Bifulco, Joseph L. Kim, Stefanie Sandra Schalm, Kevin J. Wilson, Michael Ross Palmer
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230416248
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: November 10, 2021
    Publication date: December 28, 2023
    Inventors: Kevin J. WILSON, Solymar NEGRETTI, Shawn E.R. SCHILLER, Rishi G. VASWANI, David S. HUANG, Johannes H. VOIGT
  • Compositions useful for treating disorders related to KIT
    Patent number: 11827642
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: November 28, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230365560
    Abstract: The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
    Type: Application
    Filed: May 11, 2023
    Publication date: November 16, 2023
    Inventors: Shawn E.R. SCHILLER, Solymar NEGRETTI, David S. HUANG, Kevin J. WILSON, Melek Nihan UCISIK, Richard CALDWELL
  • EGFR inhibitors
    Patent number: 11718602
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: August 8, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230149414
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 18, 2023
    Inventors: Neville John ANTHONY, Rishi G. VASWANI, David Simon MILLAN, Shawn E.R. SCHILLER, Kevin J. WILSON
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230145003
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 11, 2023
    Inventors: Kevin J. WILSON, Shawn E.R. SCHILLER, Solymar NEGRETTI
  • COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT
    Publication number: 20230129944
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Application
    Filed: November 9, 2022
    Publication date: April 27, 2023
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • Inhibitors of activin receptor-like kinase
    Patent number: 11634422
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: April 25, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian Lewis Hodous, Joseph L. Kim, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin